![Sarah Teichmann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sarah Teichmann
Directeur/Membre du Conseil chez
10X GENOMICS, INC.
Fortune : 489 082 $ au 31/05/2026
Profil
Sarah A. Teichmann is the founder of Ensocell Ltd., founded in 2023, holding the titles of Director & Chief Scientific Officer.
Dr. Teichmann is also the founder of Transition Bio, Inc. Dr. Teichmann is currently Co-Chairman at Human Cell Atlas since 2020, Chairman-Stem Cell Medicin at Cambridge Stem Cell Institute since 2024, Independent Director at 10X Genomics, Inc. since 2024, and Member of the European Molecular Biology Organization.
Former positions include Director-Studies at Trinity College, Cambridge from 1999 to 2015, Director Research-Cavendish Laboratory at the University of Cambridge from 2013 to 2024, and Director & Head-Cellular Genetics at Wellcome Trust Sanger Institute from 2016 to 2023.
Education includes undergraduate, graduate, and doctorate degrees from the University of Cambridge.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
10X GENOMICS INC CLASS A 0,01 % | 04/06/2026 | 17 279 ( 0,01 % ) | 489 082 $ | 31/05/2026 |
Postes actifs de Sarah Teichmann
| Sociétés | Poste | Début |
|---|---|---|
| 10X GENOMICS, INC. | Directeur/Membre du Conseil | 10/07/2024 |
Transition Bio, Inc.
 Transition Bio, Inc. BiotechnologyHealth Technology Provides condensate technology for drug discovery and diagnostics | Fondateur | - |
Human Cell Atlas
 Human Cell Atlas Miscellaneous Commercial ServicesCommercial Services Operates as a group of researchers using new technologies to create cellular reference maps to human body | Président | 01/04/2020 |
European Molecular Biology Organization | Corporate Officer/Principal | - |
Cambridge Stem Cell Institute | Corporate Officer/Principal | 01/04/2024 |
Anciens postes connus de Sarah Teichmann
| Sociétés | Poste | Fin |
|---|---|---|
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/04/2024 |
Wellcome Trust Sanger Institute
 Wellcome Trust Sanger Institute BiotechnologyHealth Technology Provides genomic research services | Directeur/Membre du Conseil | 01/12/2023 |
Trinity College, Cambridge
 Trinity College, Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2015 |
Formation de Sarah Teichmann
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
52
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
10X Genomics, Inc.
 10X Genomics, Inc. BiotechnologyHealth Technology Develops integrated systems and solutions for genome sequencing, exome sequencing and single cell transcriptomics | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wellcome Trust Sanger Institute
Wellcome Trust Sanger Institute BiotechnologyHealth Technology Provides genomic research services | Health Technology |
European Molecular Biology Organization | |
Trinity College, Cambridge
Trinity College, Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cambridge Stem Cell Institute | |
Human Cell Atlas
Human Cell Atlas Miscellaneous Commercial ServicesCommercial Services Operates as a group of researchers using new technologies to create cellular reference maps to human body | Commercial Services |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Provides condensate technology for drug discovery and diagnostics | Health Technology |
